Medtronic (MDT) Cash & Equivalents (2013 - 2026)

Medtronic (MDT) has 14 years of Cash & Equivalents data on file, last reported at $1.9 billion in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 12.13% year-over-year to $1.9 billion; the trailing twelve-month figure through Apr 2026 stood at $1.9 billion (down 12.13% YoY), and the FY2026 full-year result was $1.9 billion, down 12.13% from the prior year.
• Cash & Equivalents rose to $1.9 billion in Q2 2026, from $1.1 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.8 billion in Q4 2022 to a low of $1.1 billion in Q1 2026.
• A 5-year average of $2.1 billion and a median of $1.5 billion in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 72.85% in 2023 and jumped 72.74% in 2025, its largest moves.
• Tracing MDT's Cash & Equivalents over 5 years: stood at $4.8 billion in 2022, then tumbled by 72.85% to $1.3 billion in 2023, then grew by 6.33% to $1.4 billion in 2024, then fell by 8.03% to $1.3 billion in 2025, then surged by 52.03% to $1.9 billion in 2026.
• Business Quant data shows MDT's Cash & Equivalents at $1.9 billion in Q2 2026, $1.1 billion in Q1 2026, and $1.3 billion in Q4 2025.